JBT-101

DRUG3 trials

Sponsors

Corbus Pharmaceuticals Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

DermatomyositisDiffuse Cutaneous Systemic SclerosisLupusSLESystemic Lupus Erythematosus

Phase 2

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

TerminatedNCT02465437

Corbus Pharmaceuticals Inc.Diffuse Cutaneous Systemic Sclerosis

Start: 2015-08-31End: 2020-12-11Updated: 2021-04-21

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

TerminatedNCT02466243

Corbus Pharmaceuticals Inc.Dermatomyositis

Start: 2015-06-30End: 2021-01-29Updated: 2023-01-19

JBT-101 in Systemic Lupus Erythematosus (SLE)

CompletedNCT03093402

National Institute of Allergy and Infectious Diseases (NIAID)Lupus, SLE, Systemic Lupus Erythematosus

Start: 2017-12-21End: 2021-07-28Updated: 2026-05-06

Related Papers

Diverse Lenabasum pathway activation in dermatomyositis patients’ blood

Scientific Reports2025-05-181 citations

Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.

2024-09-054 citations

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.

2022-04-2936 citations